secwatch.observer — SEC 8-K summary
======================================

Issuer:     Metagenomi Therapeutics, Inc. (MGX)
CIK:        0001785279
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0000950170-25-070448
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Metagenomi NHP hemophilia A study shows durable FVIII activity through 19 months; Q1 cash $226M
--------------------------------------------------------------------------------

- Hemophilia A NHP study: durable FVIII activity at therapeutically relevant levels through ~19 months; final FVIII levels 80%, 10%, 32%.
- Cash, equivalents, and marketable securities $226.0M as of Mar 31, 2025; runway into 2027.
- R&D expenses $25.1M (Q1 2025) vs $31.4M (Q1 2024); G&A $6.8M vs $8.8M.
- Published novel compact CRISPR-associated transposases in Nature Communications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785279/000095017025070448/0000950170-25-070448-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785279/000095017025070448/mgx-20250513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-070448

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer